Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation

  1. Aaron L. Nelson, MD, PhD;
  2. Joshua T. Cohen, PhD;
  3. Dan Greenberg, PhD; and
  4. David M. Kent, MD, MS
  1. From the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts University School of Medicine, Boston, Massachusetts, and Ben-Gurion University of the Negev, Beer-Sheva, Israel.

    Abstract

    Under conditions of constrained resources, cost-saving innovations may improve overall outcomes, even when they are slightly less effective than available options, by permitting more efficient reallocation of resources. The authors systematically reviewed all MEDLINE-cited cost–utility analyses written in English from 2002 to 2007 to identify and describe cost- and quality-decreasing medical innovations that might offer favorable “decrementally” cost-effective tradeoffs—defined as saving at least $100 000 per quality-adjusted life-year lost. Of 2128 cost-effectiveness ratios from 887 publications, only 9 comparisons (0.4% of total) described 8 innovations that were deemed to be decrementally cost-effective. Examples included percutaneous coronary intervention (instead of coronary artery bypass graft) for multivessel coronary disease, repetitive transcranial magnetic stimulation (instead of electroconvulsive therapy) for drug-resistant major depression, watchful waiting for inguinal hernias, and hemodialyzer sterilization and reuse. On a per-patient basis, these innovations yielded savings from $122 to almost $12 000 but losses of 0.001 to 0.021 quality-adjusted life-years (approximately 8 hours to 1 week). These findings demonstrate the rarity of decrementally cost-effective innovations in the medical literature.

    Article and Author Information

    • Potential Conflicts of Interest: None disclosed.

    • Requests for Single Reprints: David M. Kent, MD, MS, 800 Washington Street, Box 63, Boston, MA 02111; e-mail, dkent1{at}tuftsmedicalcenter.org.

    • Current Author Addresses: Dr. Nelson: Novartis Institutes for Biomedical Research, 100 Technology Square, Room 4304, Cambridge, MA 02139.

    • Dr. Greenberg: Department of Health Systems Management, Ben-Gurion University of the Negev, PO Box 653, Beer-Sheva 84105, Israel.

    • Drs. Cohen and Kent: 800 Washington Street, Box 63, Boston, MA 02111.

    • Author Contributions: Conception and design: A.L. Nelson, D. Greenberg, D.M. Kent.

    • Analysis and interpretation of the data: A.L. Nelson, J.T. Cohen, D. Greenberg, D.M. Kent.

    • Drafting of the article: A.L. Nelson, D. Greenberg, D.M. Kent.

    • Critical revision of the article for important intellectual content: A.L. Nelson, J.T. Cohen, D. Greenberg, D.M. Kent.

    • Final approval of the article: A.L. Nelson, J.T. Cohen, D. Greenberg, D.M. Kent.

    • Statistical expertise: D. Greenberg.

    • Administrative, technical, or logistic support: A.L. Nelson, D.M. Kent.

    • Collection and assembly of data: J.T. Cohen.

    « Previous | Next Article »Table of Contents